| BACKGROUND AND AIM:Studies have shown that serum omentin-1 levels were lower in patients with CAD than in control participants.Omentin were correlated with energy metabolism,inhibiting inflammation,regulating cardiovascular function.It has properties of anti-inflammatory,antioxidant,antiatherogenic and ischemia-induced revascularization,these protective roles in the pathophysiology of cardiovascular disease suggested that omentin-1 may serve as a molecule which connected inflammatory with CAD,and will possibly become a novel therapeutic target for atherosclerosis and CAD,Overall,reports regarding the effects of drugs for CAD therapy on serum omentin-1 levels are not available.The aim of the present study was to investigate the effect of atorvastatin on serum levels of omentin-1 in patients with CAD.METHODS:One-hundred and ninety-eight patients with newly diagnosed CAD undergoing coronary angiography primarily for chest pain or dyspnea on exertion were divided into two groups:those with acute coronary syndrome(ACS)and those with stable angina pectoris(SAP).We included only newly diagnosed patients who had taken no lipid-lowering agent preceding our study.Patients with diabetes mellitus(DM),valvular heart disease,coronary artery bypass graft surgery,malignant disease,infectious disease,inflammatory disease such as collagen disease,neoplasia,hematological disorders,advanced renal disease,and liver disease were excluded.All patients were randomized to receive atorvastatin therapy at a dose of either 20 or 40 mg/day for 12 weeks.Clinical characteristics including age,smoking,smoking,family history of CAD,BMI were collected before any mediation.Blood sampling and assessment of clinical parameters,such as omentin-1,LDL-C,HDL-C,triglycerides,fasting glucose,hs-CRP and IL-6 were performed at baseline and at the end of the study.RESULTS:Atorvastatin at doses of 20 and 40 mg significantly reduced LDL-C(ACS-20mg,P<0.001;ACS-40mg,P<0.001;SAP-20mg,P<0.001;SAP-40mg,P<0.001),IL-6(ACS-20mg,P<0.001;ACS-40mg,P<0.001;SAP-20mg,P=0.012;SAP-40mg,P<0.001),and hs-CRP(ACS-20mg,P<0.001;ACS-40mg,P<0.001;SAP-20mg,P<0.001;SAP-40mg,P<0.001)levels and increased omentin-1(ACS-20mg,P=0.007;ACS-40mg,P<0.001;SAP-20mg,P=0.017;SAP-40mg,P<0.001)and HDL-C(ACS-20mg,P=0.007;ACS-40mg,P=0.001;SAP-20mg,P<0.001 SAP-40mg,P<0.001)levels from baseline after 12 weeks of administration in patients with ACS and in those with SAP.Atorvastatin at 20 and 40mg increased omentin-1 levels by 6.68 and 16.90ng/ml,respectively,compared with baseline values in patients with ACS after 12 weeks of administration.The difference between the two doses was statistically significant(P=0.003).Serum omentin-1 levels increased by 5.27ng/ml in the 20mg group and by 13.06ng/ml in the 40mg group in patients with SAP,and the difference was statistically significant(P=0.012).In addition,changes in IL-6(ACS,P<0.001;SAP,P=0.022)and LDL-C levels(ACS,P<0.001;SAP,P=0.001)were significantly different between the 20 and 40mg groups both in patients with ACS and in those with SAP.Changes in hs-CRP levels produced by different doses of atorvastatin were significantly different in the ACS group alone(P=0.036).The observed increment in serum omentin-1 levels in patients with CAD was associated with changes in LDL-C(r=-0.145,P=0.041),IL-6(r=-0.162,P=0.023),and hs-CRP levels(r=-0.185,P=0.009),as shown by univariate analysis.Changes in LDL-C(?=-0.158,P=0.027)and IL-6(?=-0.154,P=0.044)both remained independent determinants of omentin-1 alterations in standard multiple regression analysis(R2=0.122,P=0.006)after adjusting for age,sex,smoking,family history of CAD,and BMI.CONCLUSION:Atorvastatin increased serum omentin-1 concentrations in patients with CAD in a dose-dependent manner.The atorvastatin-induced increment in serum omentin-1 levels represents the novel cardiovascular-protectivecapacity of the drugbesidesdecreasing the levels LDL-C,stabilizing atherosclerotic plaques,anti-inflammatory and antioxidant effects. |
PDF Full Text Request